Disc Sees Promise In Hematology With Former Roche Schizophrenia Candidate

 
• By Joseph Haas

Phase II data in two rare hematological disorders show potential for transformative therapeutic benefit, according to analysts. The company awaits more results for further confirmation.

Sun sensitive
Disc's bitopertin shows ability to improve sunlight tolerance in Phase II trial • Source: Shutterstock

More from Clinical Trials

More from R&D